5-(4-溴苯基)-4H-1,2,4-三唑-3-胺 | 54464-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(4-溴苯基)-4H-1,2,4-三唑-3-胺
• 英文名称: 5-(4-bromo-phenyl)-1H-[1,2,4]triazol-3-ylamine
• 英文别名: 5-(4-bromophenyl)-1H-1,2,4-triazol-3-amine
• CAS: 54464-13-0
• 化学式: C₈H₇BrN₄
• mdl: MFCD00846705
• 分子量: 239.074
• InChiKey: VXTCEROZEXTJAB-UHFFFAOYSA-N

物化性质

• 密度：
  1.732

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090
• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P305+P351+P338,P330,P332+P313,P337+P313,P362,P403+P233,P405,P501
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  5-(4-溴苯基)-4H-1,2,4-三唑-3-胺 在 硫酸 、 水 、 sodium nitrite 作用下， 以 溶剂黄146 为溶剂， 反应 1.0h， 以27%的产率得到5-(4-Bromo-phenyl)-3-nitro-1H-[1,2,4]triazole
  参考文献：
  名称：

  Tolstyakov; Pevzner, Russian Journal of Organic Chemistry, 1997, vol. 33, # 12, p. 1803 - 1804

  摘要：

  DOI：
• 作为产物：
  描述：

  对溴苯甲酰肼 在 sodium hydroxide 作用下， 以 水 为溶剂， 反应 72.0h， 生成 5-(4-溴苯基)-4H-1,2,4-三唑-3-胺
  参考文献：
  名称：

  A structure–activity relationship study of 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione and its 5-thioxo analogues on anti-thymidine phosphorylase and associated anti-angiogenic activities

  摘要：

  Thirty-three 1,2,4-triazolo[1,5-a][1,3,5]triazin-5,7-dione and its 5-thioxo analogues were designed and synthesized which contained different substituents at meta- and/or para-positions of 2-phenyl or 2-benzyl ring attached to the fused ring structure. The preliminary pharmacological evaluation demonstrated that the 5-thioxo analogues of 1,2,4-triazolo[1,5-a][1,3,5]triazine exhibited a varying degree of inhibitory activity towards thymidine phosphorylase, comparable or better than reference compound, 7-Deazaxanthine (7-DX, 2) (IC50 value = 42.63 mu M). Moreover, compounds 5q and 6i displayed a mixed-type of inhibitory mechanism in the presence of variable concentrations of thymidine (dThd). In addition, selected compounds were found to have a noticeable inhibitory effect on the expression of angiogenesis markers, including VEGF and MMP-9 in MDA-MB-231 breast cancer cells. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.06.051

文献信息

• 3-Aryl/Heteroaryl-5-amino-1-(3′,4′,5′-trimethoxybenzoyl)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization
  作者：Romeo Romagnoli、Filippo Prencipe、Paola Oliva、Stefania Baraldi、Pier Giovanni Baraldi、Andrea Brancale、Salvatore Ferla、Ernest Hamel、Roberta Bortolozzi、Giampietro Viola

  DOI：10.1016/j.bioorg.2018.06.037

  日期：2018.10

  at the 3-position of the 5-amino-1,2,4-triazole system. Most of the twenty-two tested compounds showed moderate to potent antiproliferative activities against a panel of solid tumor and leukemic cell lines, with four (5j, 5k, 5o and 5p) showing strong antiproliferative activity (IC50 < 1 μM) against selected cancer cells. Among them, several molecules preferentially inhibited the proliferation of leukemic

  已知许多天然和合成物质会干扰微管蛋白的动态组装，从而阻止微管的形成。在我们寻找有效的和选择性的抗肿瘤剂中，合成了一系列新的1-（3'，4'，5'-三甲氧基苯甲酰基）-5-氨基-1,2,4-三唑。这些化合物具有不同的杂环，包括噻吩，呋喃或三个同分异构的吡啶，并且它们在5-氨基-1,2,4-三唑体系的3位上具有带电子释放或吸电子取代基的苯环。 。测试的22种化合物中的大多数对一组实体瘤和白血病细胞系均显示出中度至强效的抗增殖活性，其中4种（5j，5k，5o和5p） 对选定的癌细胞显示出强大的抗增殖活性（IC 50 <1μM）。其中，有几种分子优先抑制白血病细胞系的增殖，显示Jurkat和RS4; 11细胞的IC 50值比源自实体瘤的三系（HeLa，HT-29和MCF- 7个单元格）。化合物5k强烈抑制微管蛋白组装，IC 50值为0.66μM，是在CA-4的同时实验中获得的一半（IC 50  =
• NOVEL COMPOUNDS THAT ARE ERK INHIBITORS
  申请人：Cooper Alan B.

  公开号：US20110189192A1

  公开（公告）日：2011-08-04

  Disclosed are the ERK inhibitors of formula 1.0: and the pharmaceutically acceptable salts, and solvates thereof. Q is a tetrahydropyridinyl ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.

  本发明公开了化学式1.0的ERK抑制剂，以及其药学上可接受的盐和溶剂化物。其中，Q代表四氢吡啶环。所有其他取代基的定义如本文所述。此外，本发明还公开了使用化合物1.0治疗癌症的方法。
• TRIAZOLE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
  申请人：THE GREEN CROSS CORPORATION

  公开号：EP0710654A1

  公开（公告）日：1996-05-08

  An agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, an agent for the prophylaxis and treatment of allergic diseases, an agent for the prophylaxis and treatment of eosinophil-related diseases and an eosinophilia inhibitor, comprising, as an active ingredient, a series of triazole derivatives of the following formula (I) or the following formula (III) wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. A novel monocyclic or bicyclic triazole derivative. The agent for the prophylaxis and treatment of immune-related diseases, in particular, immunosuppressant, the agent for the prophylaxis and treatment of allergic diseases, the agent for the prophylaxis and treatment of eosinophil-related diseases, the eosinophilia inhibitor and the novel triazole derivative of the present invention all have superior eosinophilia-inhibitory action and lymphocyte activation-inhibitory action. They are low toxic and persistent in action. They are particularly effective in the treatment of accumulation and activation of eosinophil and lymphocytes, inflammatory respiratory tract diseases, eosinophil-related diseases such as eosinophilia, and immune-related diseases.

  一种预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂，一种预防和治疗过敏性疾病的制剂，一种预防和治疗嗜酸性粒细胞相关疾病的制剂和一种嗜酸性粒细胞增多抑制剂，其活性成分包括下式（I）的一系列三唑衍生物 或下式（III） 其中各符号如说明书中所定义，或其药学上可接受的盐。一种新型单环或双环三唑衍生物。本发明的预防和治疗免疫相关疾病的制剂，特别是免疫抑制剂、预防和治疗过敏性疾病的制剂、预防和治疗嗜酸性粒细胞相关疾病的制剂、嗜酸性粒细胞抑制剂和新型三唑衍生物都具有优异的嗜酸性粒细胞抑制作用和淋巴细胞活化抑制作用。它们毒性低，作用持久。它们对治疗嗜酸性粒细胞和淋巴细胞的积聚和活化、呼吸道炎症性疾病、嗜酸性粒细胞相关疾病（如嗜酸性粒细胞增多症）以及免疫相关疾病特别有效。
• Synthesis and Pharmacological Activity of Triazole Derivatives Inhibiting Eosinophilia
  作者：Youichiro Naito、Fumihiko Akahoshi、Shinji Takeda、Takehiro Okada、Masahiko Kajii、Hiroko Nishimura、Masanori Sugiura、Chikara Fukaya、Yoshio Kagitani

  DOI：10.1021/jm9507993

  日期：1996.1.1

  In order to develop novel antiasthmatic agents based on a new mechanism of action, a series of 3-substituted 5-amino-1-[(methylamino)(thiocarbonyl)]-1H-1,2,4-triazole derivatives were synthesized and evaluated in a model in which eosinophilia was induced in the ah-way through intravenous (iv) injection of Sephadex particles on days 0, 2, and 5. After screening of several hundred derivatives, we finally identified the highly potent eosinophilia inhibitor 5-amino-3-(4-chlorophenyl)-1-[(methylamino)(thiocarbonyl)]-1H-triazole (23c, GCC-AP0341), which had ID50 values of 0.3 and 0.07 mg/kg when administered orally (os) and intraperitoneally tip), respectively. This compound showed complete inhibition of the hypersensitivity induced by ascaris inhalation at an ip dose of 1 mg/kg as well as low toxicity, with an LD(50) value of > 2.0 g/kg in mice. Extensive study of its mechanism of action revealed that 23c inhibited eosinophil survival induced by interleukin-5 (IL-5), but had little or no effect on leukotriene D-4 (LTD(4)) or platelet-activating factor (PAF)-induced responses. Taken together, these results suggest 23e as a novel candidate for the treatment of chronic asthma. Further studies are now underway.
• Synthesis and<i>in vitro</i>Evaluation of 1,2,4-Triazolo[1,5-<i>a</i>][1,3,5]triazine Derivatives as Thymidine Phosphorylase Inhibitors
  作者：Hriday Bera、Anton V. Dolzhenko、Lingyi Sun、Sayan Dutta Gupta、Wai-Keung Chui

  DOI：10.1111/cbdd.12171

  日期：2013.9

  In our lead finding program, a series of 1,2,4‐triazolo[1,5‐a][1,3,5]triazine derivatives were synthesized, and their in vitro thymidine phosphorylase inhibitory potential was explored. Among the different derivatives, compounds having keto group (C = O) at C7 and thioketo group (C = S) at C5 positions showed varying degrees of TP inhibitory activity comparable with positive control, 7‐deazaxanthine (7‐DX, 2) (IC50 value = 42.63 μm). Enzyme inhibition kinetics study suggested that compound IVn behaved as a mixed‐type inhibitor of the enzyme with respect to thymidine (dThd) as a variable substrate. Compound IVn was also found to inhibit PMA‐induced MMP‐9 expression in MDA‐MB‐231 cells at sublethal concentrations. Computational docking study was performed to illustrate the enzyme inhibition kinetics and to explore the ligand–enzyme interactions.